Cyxone has engaged senior scientific experts to support the development of the drug projects. All members of the Scientific Advisory Board are acknowledged experts within their respective fields, including a member of the Nobel Assembly. They add important experience from both the scientific and industrial areas to Cyxone.
Chairman of the scientific advisory
Christian Gruber is a research group leader and Associate Professor at the Medical University of Vienna (Austria). He studied Biochemistry at the University of Tübingen, Germany, and Molecular Biotechnology at the Queensland University of Technology, Australia, and received a Ph.D. in Molecular Biosciences from The University of Queensland. For his achievements he has received several scientific awards, such as the 2013 Heribert Konzett Award of the Austrian Pharmacological Society, the 2014 Young Investigator Silver Award of the International Union of Basic and Clinical Pharmacology, and the 2014 Dr. Willmar Schwabe Award of the Society for Medicinal Plant and Natural Product Research. The research focus of his team is to study biological function sand pharmacological mechanisms of nature-derived peptides isolated from plants and invertebrates (e.g. peptide hormones, neuropeptides and peptide toxins), and the development of novel peptide therapeutics. He is a member of the scientific affairs committee of the European Peptide Society and member elect of the Max-Bergmann-Kreis.
Maarten Kraan holds a medical degree and a Ph.D. in immunology from Leiden University, The Netherlands, and a board certification in Rheumatology. During his academic career he worked at Leiden University and as associate professor at the University of Amsterdam. He has held several management positions within drug research, clinical development and regulatory affairs in pharmaceutical companies in both Europe and USA. Maarten is CMO at AM Pharma, a board member of Toleranzia AB and Vicore AB. At Vicore, he is also the chair of the scientific committee.
Professor Rikard Holmdahl holds a medical degree and a Ph.D. in immunology from Uppsala University, Sweden, and has held several senior scientific positions within academia. In 1990 he was appointed Associate Professor at the Swedish Medical Research Council, and in 1993 he set up the Medical Inflammation Research group at Lund University as full Professor at the university. Since 2008 he holds the position of Professor at the Karolinska Institutet (KI) in Stockholm, and since 2014 he is a member of the Nobel Assembly. In addition to his position at KI, he is also a scientific advisor and consultant for biotech and biomedical companies. Rikard Holmdahl actively performs research in the areas of RA and MS and has formerly been intimately involved in the understanding of Rabeximod mechanism of action.